Citation: Ms. Litwin et Df. Penson, HEALTH-RELATED QUALITY-OF-LIFE IN MEN WITH PROSTATE-CANCER, PROSTATE CANCER AND PROSTATIC DISEASES, 1(5), 1998, pp. 228-235
Citation: Jw. Moul et al., PREOPERATIVE AND OPERATIVE FACTORS TO PREDICT INCONTINENCE, IMPOTENCEAND STRICTURE AFTER RADICAL PROSTATECTOMY, PROSTATE CANCER AND PROSTATIC DISEASES, 1(5), 1998, pp. 242-249
Authors:
BENAIM EA
MONTOYA JD
SABOORIAN MH
LITWILLER S
ROEHRBORN CG
Citation: Ea. Benaim et al., CHARACTERIZATION OF PROSTATE SIZE, PSA AND ENDOCRINE PROFILES IN PATIENTS WITH SPINAL-CORD INJURIES, PROSTATE CANCER AND PROSTATIC DISEASES, 1(5), 1998, pp. 250-255
Authors:
STENNER J
DEANTONI EP
ODONNELL C
STONE NN
MCLEOD DG
CRAWFORD ED
Citation: J. Stenner et al., PREVALENCE AND NATURAL-HISTORY OF URINARY SYMPTOMS IN A LONGITUDINAL NATIONAL PROSTATE-CANCER SCREENING (COMMUNITY-BASED) STUDY, PROSTATE CANCER AND PROSTATIC DISEASES, 1(5), 1998, pp. 256-261
Authors:
TORRING N
SORENSEN BS
BOSCH ST
KLOCKER H
NEXO E
Citation: N. Torring et al., AMPHIREGULIN IS EXPRESSED IN PRIMARY CULTURES OF PROSTATE MYOFIBROBLASTS, FIBROBLASTS, EPITHELIAL-CELLS, AND IN PROSTATE TISSUE, PROSTATE CANCER AND PROSTATIC DISEASES, 1(5), 1998, pp. 262-267
Authors:
BORRE M
STRAUSBOLGRON B
NERSTROM B
OVERGAARD J
Citation: M. Borre et al., IMMUNOHISTOCHEMICAL BCL-2 AND KI-67 EXPRESSION PREDICT SURVIVAL IN PROSTATE-CANCER PATIENTS FOLLOWED EXPECTANTLY, PROSTATE CANCER AND PROSTATIC DISEASES, 1(5), 1998, pp. 268-275
Citation: B. Lukacs et al., 3-YEAR PROSPECTIVE-STUDY OF 3228 CLINICAL BPH PATIENTS TREATED WITH ALFUZOSIN IN GENERAL-PRACTICE, PROSTATE CANCER AND PROSTATIC DISEASES, 1(5), 1998, pp. 276-283
Authors:
PENSON DF
LITWIN MS
LUBECK DP
FLANDERS S
PASTA DJ
CARROLL PR
Citation: Df. Penson et al., TRANSITIONS IN HEALTH-RELATED QUALITY-OF-LIFE DURING THE FIRST 9 MONTHS AFTER DIAGNOSIS OF PROSTATE-CANCER (VOL 1, PG 134, 1998), PROSTATE CANCER AND PROSTATIC DISEASES, 1(5), 1998, pp. 284-284
Authors:
PARTIN AW
BRAWER MK
SUBONG ENP
KELLEY CA
COX JL
BRUZEK DJ
PANNEK J
MEYER GE
CHAN DW
Citation: Aw. Partin et al., PROSPECTIVE EVALUATION OF PERCENT FREE-PSA AND COMPLEXED-PSA FOR EARLY DETECTION OF PROSTATE-CANCER, PROSTATE CANCER AND PROSTATIC DISEASES, 1(4), 1998, pp. 197-203
Citation: Ar. Williams et P. Whelan, USE OF INTRAVENOUS FOSFESTROL TETRASODIUM (HONVAN) INFUSION IN TREATMENT OF SYMPTOMATIC ADVANCED PROSTATE-CANCER, PROSTATE CANCER AND PROSTATIC DISEASES, 1(4), 1998, pp. 204-207
Authors:
BROWN LG
WEGNER SK
WANG H
BUHLER KR
ARFMAN EW
LANGE PH
VESSELLA RL
Citation: Lg. Brown et al., A NOVEL MONOCLONAL-ANTIBODY 107-1A4 WITH HIGH PROSTATE SPECIFICITY - GENERATION, CHARACTERIZATION OF ANTIGEN EXPRESSION, AND TARGETING OF HUMAN PROSTATE-CANCER XENOGRAFTS, PROSTATE CANCER AND PROSTATIC DISEASES, 1(4), 1998, pp. 208-215
Authors:
BEAN JM
MONTANA GS
CLOUGH RW
KING SC
BENTEL GC
MARKS LB
ANSCHER MS
Citation: Jm. Bean et al., STANDARD VS CONFORMAL RADIATION-THERAPY FOR ADENOCARCINOMA OF THE PROSTATE - NO DIFFERENCE, PROSTATE CANCER AND PROSTATIC DISEASES, 1(4), 1998, pp. 216-222
Citation: R. Kirby et A. Jardin, DOXAZOSIN IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA - A REVIEWOF THE SAFETY PROFILE IN OLDER PATIENTS (VOL 1, PG 84, 1997), PROSTATE CANCER AND PROSTATIC DISEASES, 1(4), 1998, pp. 223-223
Citation: Jl. Letran et Mk. Brawer, MANAGEMENT OF RADIATION FAILURE FOR LOCALIZED PROSTATE-CANCER, PROSTATE CANCER AND PROSTATIC DISEASES, 1(3), 1998, pp. 119-127